DATA GRAPHICS | Data Byte
Data comp: MoonLake sets efficacy bar in hidradenitis suppurativa
Sonelokimab shows 29% improvement vs. placebo on HiSCR75 endpoint, besting two other programs
June 26, 2023 10:13 PM UTC
MoonLake has set a new efficacy standard in hidradenitis suppurativa that so far gives it a best-in-class profile.
MoonLake Immunotherapeutics AG (NASDAQ:MLTX) gained $20.07 (78%) to $45.95 on Monday after announcing over the weekend data from the Phase II MIRA study that showed anti-IL-17A/F inhibitor sonelokimab met the primary endpoint of patients achieving a HiSCR75 response vs. placebo (43.3% vs. 14.7%; p=0.0002) at week 12. ...